Abstract:Recent research has indicated that the abnormal expression of the deubiquitinase USP7 induces tumorigenesis via multiple cell pathways, and in particular, the p53-MDM2-USP7 pathway is well understood. USP7 is emerging as a promising target for cancer therapy. However, there are limited reports on USP7 inhibitors. Here we report design, synthesis and biological evaluation of novel quinazolin-4(3H)-one derivatives as potent USP7 inhibitors. Our results indicated that the compounds C9 and C19 exhibited the greatest potency against the USP7 catalytic domain, with IC50 values of 4.86 μM and 1.537 μM, respectively. Ub-AMC assays further confirmed IC50 values of 5.048 μM for C9 and 0.595 μM for C19. MTT assays indicated that gastric cancer MGC-803 cells were more sensitive to these compounds than BGC-823 cells. Flow cytometry analysis revealed that C9 restricted cancer cell growth at the G0/G1 and S phases and inhibited the proliferation and clone formation of MGC-803 cells. Further biochemical experiments indicated that C9 decreased the MDM2 protein level and increased the levels of the tumour suppressors p53 and p21 in a dose-dependent manner. Docking studies predicted that solvent exposure of the side chains of C9 and C19 would uniquely form hydrogen bonds with Met407 of USP7. Additionally, C9 exhibited a remarkable anticancer effect in a zebrafish gastric cancer MGC-803 cell model. Our results demonstrated that quinazolin-4(3H)-one derivatives were suitable as leads for the development of novel USP7 inhibitors and especially for anti-gastric cancer drugs.

Virtual screening of natural products targeting ubiquitin-specific protease 7

Virtual Screening Inhibitors of Ubiquitin‐specific Protease 7 combining Pharmacophore Modeling and Molecular Docking

Discovery of Ubiquitin-Specific Protease 7 (USP7) Inhibitors with Novel Scaffold Structures by Virtual Screening, Molecular Dynamics Simulation, and Biological Evaluation

Identification of new leads against ubiquitin specific protease-7 (USP7): a step towards the potential treatment of cancers

Gardenin B, a Natural Inhibitor for USP7: in Vitro Evaluation and in Silico Identification

In Silico Analysis of USP7 Inhibitors Based on Building QSAR Models and Fragment Design for Screening Marine Compound Libraries

USP7: Target Validation and Drug Discovery for Cancer Therapy

Generation and Validation of Intracellular Ubiquitin Variant Inhibitors for USP7 and USP10.

Design, synthesis, biological evaluation and structure-activity relationship study of quinazolin-4(3H)-one derivatives as novel USP7 inhibitors

Synthesis and Biological Evaluation of Thiazole Derivatives As Novel USP7 Inhibitors.

Molecular Docking‐based Virtual Screening and Dynamics Simulation Study of Novel and Potential SIRT7 Inhibitors

Cheminformatics-aided discovery of potential allosteric site modulators of ubiquitin-specific protease 7

Structure-Guided Discovery of Selective USP7 Inhibitors with In Vivo Activity

In silico screening and computational evaluation of novel promising USP14 inhibitors targeting the palm-thumb pocket

Advances in research on a novel anticancer target USP7 and its inhibitors

Structure-based Virtual Screening of Novel USP5 Inhibitors Targeting the Zinc Finger Ubiquitin-Binding Domain

Discovery of Potent Small-Molecule USP8 Inhibitors for the Treatment of Breast Cancer Through Regulating ERα Expression

Characterization of Naturally Occurring Pentacyclic Triterpenes As Novel Inhibitors of Deubiquitinating Protease USP7 with Anticancer Activity in Vitro

Discovery of selective and potent USP22 inhibitors via structure-based virtual screening and bioassays exerting anti-tumor activity

USP7 inhibitor P5091 inhibits Wnt signaling and colorectal tumor growth

Targeting Ubiquitin-Specific Protease 7 (USP7) in Cancer: A New Insight to Overcome Drug Resistance